Analysis of FMC Corporation’s Q2 2026 10-Q
Filing dated 30 July 2026 for the quarter ended 30 June 2026 · checked against the earnings calls on 5 February, 30 April and 30 July · read in September 2026 · updated 15 October
Original analysis issued 25 September 2026. This report also incorporates later FMC disclosures; the updates are distinguished from the original findings in the Evidence & Outcomes Ledger ↓.
Where the filing and the story diverge
FMC’s story was a 2026 trough, a second-half recovery and a balance sheet repaired by $1B of deals. The 10-Q showed that recovery resting on the sales channel: $632.4M of rebates owed to customers, prepayments from them almost gone, and the leverage covenant switched off until December. On 15 October the channel gave way.
- Three findings: Rebates owed to customers reached $632.4M; The leverage covenant is switched off until December; Q2 cash flow leaned on a $200M licence prepayment. Each is set out below with the figure, where it sits in the filing and what would close it.
- Since the read. FMC cut Q3 revenue to $65M to $125M, against $840M to $900M guided in July, and set out $625M to $675M of commercial actions: lower prices on FMC stock held by distributors in Brazil, Argentina, the US and Canada, and a move away from its US high-rebate pricing model.
- On the calls. 2 of 3 findings were sidestepped or never asked.
- Management’s record. 1 kept, 1 changed, 2 missed, 1 reversed on earlier promises.
- What it does not show. Nothing here shows misstatement or a covenant breach.
- Q2 revenue
- $867.1M, down 17.5%; $841M excluding India
- Adjusted EBITDA and EPS
- $153M, above guidance; adjusted EPS $0.26
- GAAP result
- Net loss attributable $186.6M; diluted EPS −$1.49
- July guidance, full year
- Revenue $3.5B to $3.7B; adjusted EBITDA $620M to $680M; free cash flow $75M to $225M
- Debt plan
- About $1B of deals: India $252M, Corteva $200M, Newark $114M, Tessenderlo $400M
Three findings, ranked by importance
Each is set out in full below: what the filing shows, the numbers, the evidence and what would close it.
Rebates owed to customers reached $632.4M
Up 51.5% from December while Q2 revenue fell 17.5%. Price concessions owed on product already sold into the channel.
Accrued customer rebates rose from $417.4M to $632.4M in six months, equal to about 73% of Q2 revenue. Rebates build every first half (H1 2025 added $304.5M, H1 2026 $220.8M), so the build alone is seasonal. What changed is the setting: FMC was cutting Rynaxypyr prices through the half to defend volume against generics, and advance payments from customers fell from $453.1M to $35.5M. FMC entered the second half owing the channel more than ever, with almost no prepaid demand behind it.
Customer advances that funded the first half ran off: $417.6M of the December balance was recognised as revenue in H1, leaving $35.5M of short-term advances at June 30.
Evidence“The amount of revenue recognized in the six months ended June 30, 2026 that was included in the opening contract liability balance is $417.6 million.”Note 3, Revenue Recognition
The leverage covenant is switched off until December
Not measured in Q2 or Q3 under the April amendment; back in Q4 at 6.75x. The limit has been loosened twice since December.
In December 2025 lenders allowed total leverage of up to 6.0x through 2026. In April a second amendment made the revolver fully secured, suspended the total-leverage test for Q2 and Q3, and reinstated it in Q4 at 6.75x through December 2027, with a new 3.5x cap on secured debt. At June 30 total leverage would have been about 5.6x; secured leverage was 1.66x and interest cover 2.78x against a 2.0x minimum. Q3 EBITDA was guided at only $120M to $140M, so trailing earnings were already falling into the Q4 test.
Debt was pushed long: $1.2B of senior secured notes issued in May, $500M of October 2026 notes redeemed, short-term debt down from $1,305.1M to $326.3M and long-term debt up from $2,769.8M to $3,954.3M.
Evidence“The maximum total leverage ratio is not measured formally for the second or third quarters under the terms of the amendment, but would've been approximately 5.6x.”CFO, Q2 2026 earnings call; revolver amendment of 16 April 2026
Q2 cash flow leaned on a $200M licence prepayment
Without the Corteva prepayment, Q2 free cash flow was about $157M, after H1 operating cash of −$237.9M.
Corteva paid $200M upfront for rimisoxafen supply. FMC booked it as long-term deferred revenue and it flows through operating cash, lifting Q2 free cash flow to $357M; without it the quarter was about $157M. Other cash supports were one-offs too: the India business, carried at $350M, is being sold for $252M with a $17M currency gain waiting to be released into income at close; $70.6M of Latin American receivables were written off as FMC moved to direct sales; and receivables sold without recourse fell to $68.2M from $206.2M a year earlier.
Illustrative Helmledgers adjustment, not a company-reported metric. The $200M was cash received and included in reported operating cash flow; this bridge isolates free cash flow excluding that upfront payment.
H1 operating cash flow from continuing operations was −$237.9M. The dividend was cut to $0.08 a quarter, so H1 dividends paid were $20.2M against $145.5M a year earlier.
Evidence“Corteva made an initial prepurchase cash payment of $200.0 million for rimisoxafen to be supplied by FMC, which was recognized as deferred revenue and was included in Other long-term liabilities on the consolidated balance sheet as of June 30, 2026.”Note 3, Revenue Recognition
Other findings, checked and set aside
Each item was tested against the filing. None changes the lead findings above.
| Item | What the filing shows, and why it is not a lead finding |
|---|---|
| Revenue drivers | Q2 −17.5%: volume −10%, price −7%, India −5%, FX +2% |
| Gross margin | Up to 39.5% from 38.7% despite lower sales |
| SG&A and R&D | SG&A 20.7% of revenue from 16.8%; R&D cut to $60.4M from $66.4M |
| Restructuring | $222.3M in Q2, $299.3M in H1; Project Foundation write-downs $198.9M |
| Latin America receivables | $70.6M written off on the move to direct sales |
| Receivables | Flat at $2,070.5M into a weaker quarter; about 218 days of Q2 sales |
| Tax | $110.6M H1 tax expense on a $343.5M pre-tax loss |
| Environmental and discontinued | Environmental accrual $562.9M; discontinued operations −$13.4M in H1 |
| Vendor and receivable financing | Vendor financing guarantees $39.6M; $96.4M of receivables securitised in H1 |
| Pre-tax bridge | Ties exactly: −$119.7M − $3.3M − $71.3M = −$194.3M. No unexplained residual. |
What FMC disclosed
The read was completed in September 2026, before this update. Each lead finding against what the company then disclosed, including what the read missed.
FMC cut Q3 revenue to $65M to $125M, against $840M to $900M guided in July, and set out $625M to $675M of commercial actions: lower prices on FMC stock held by distributors in Brazil, Argentina, the US and Canada, and a move away from its US high-rebate pricing model. The shares fell 35%.
Lead findings against what was disclosed
4 items trackedRebates owed to customers reached $632.4M
FMC said its US selling model had been a “high gross-price and high-rebate structure” and is moving away from it, alongside price cuts on higher-priced FMC stock held by channel customers. It said the issue had been addressed “incrementally over several quarters”.
The leverage covenant is switched off until December
FMC expects to be in compliance at September 30, but intends to seek “potential further modifications to covenants over the next year”. Q3 adjusted EBITDA guidance moved from $120M to $140M to −$565M to −$510M, ahead of the Q4 test.
Q2 cash flow leaned on a $200M licence prepayment
No update on cash. Full-year guidance, the year-end net debt target and the timing of the $1B deals should all be treated as open until the Q3 results.
Intangible impairment
Not flagged as a risk in the Q2 read. FMC identified a triggering event and may record a material non-cash impairment of intangible assets in Q3.
Adding the $625M to $675M of actions back, Q3 revenue would have been about $690M to $800M and adjusted EBITDA about $110M at the midpoint, an underlying miss of roughly 14% against July’s guidance. Most of the swing is FMC choosing to clear the channel in one quarter rather than over several.
Helmledgers calculation from the company’s ranges.What management said about each finding
Checked against the calls on 5 February, 30 April and 30 July.
No analyst asked about rebates or channel stock on any of the three calls. In July management put lower Q3 volume down to North American distributors moving orders into Q4.
“North America distributors managing inventory by shifting orders from Q3 to Q4”
Asked about maturities and covenants in February, the CFO said FMC had a good plan to manage within the existing covenants; ten weeks later the test was suspended. In July he called FMC comfortably in compliance, and no analyst asked.
“We are comfortably in compliance with our covenant metrics.”
The CFO volunteered that the payment sits as a long-term advance and does not affect working capital, and that this structure may not recur. No analyst asked how much of free cash flow came from licensing.
“the specific structure of the rimisoxafen licensing agreement may not recur”
9 disclosures moved
10-Q Q2 2026 compared with the 10-K for FY 2025.
| Status | Disclosure | Before | Now |
|---|---|---|---|
| Changed | Accrued customer rebates Balance sheet | $417.4M | $632.4M |
| Changed | Advance payments from customers Note 3 | $453.1M | $35.5M |
| New | Long-term advance from Corteva Note 3 | Not present | $200.0M deferred revenue in other long-term liabilities |
| Changed | Leverage covenant Revolving credit facility | Up to 6.0x through 2026 | Not tested Q2 and Q3; 6.75x from Q4; secured debt capped at 3.5x |
| Changed | Short-term debt Balance sheet | $1,305.1M | $326.3M |
| Changed | Long-term debt Balance sheet | $2,769.8M | $3,954.3M after $1.2B of secured notes |
| Changed | India business held for sale Note 1 | Carried at $450.0M | $350.0M; agreed sale at $252M |
| Changed | Property, plant and equipment Note 7 | $707.4M | $554.7M after plant write-downs |
| Changed | Total equity Equity statement | $2,098.9M | $1,661.1M |
Four of the nine point the same way: more owed to customers, less prepaid by them, debt pushed long, and the leverage covenant switched off. The customer-rebate line is the one most readers will miss.
5 markers for 29 October
Set before the numbers, so the read can be checked afterwards.
| Marker | Now | Gap widens if | Gap closes if | Result |
|---|---|---|---|---|
| Accrued customer rebates | $632.4M at June 30 | Concessions charged on top of the accrual, or a large balance left after Q3 | Concessions settled against the accrual and the US gross-to-net gap narrowed | Awaiting |
| Total leverage covenant | Not tested; about 5.6x at June 30 | A further amendment or waiver before the Q4 test | Tested in Q4 at or under 6.75x | Awaiting |
| Q3 revenue and adjusted EBITDA | $65M to $125M; −$565M to −$510M | Below the October range, or the range moves again | Within range, with channel stock cleared | Awaiting |
| Non-cash impairment | Possible, not quantified | A large charge against the $2.31B of other intangibles | Small or none | Awaiting |
| Full-year free cash flow | $75M to $225M guided in July | Guidance cut or turned negative | Guidance held | Awaiting |
The markers are set before the numbers so the read can be checked afterwards. A widening gap does not by itself mean anything is wrong; it means the reported story and the filing are moving further apart.
How the read is scoring
Markers and promises set before the numbers, marked as results come in.
| Type | Item | Set before the numbers | Result |
|---|---|---|---|
| Promise | Q3 revenue | $840M to $900M | Missed now $65M to $125M (15 Oct) |
| Promise | Q3 adjusted EBITDA | $120M to $140M | Missed now −$565M to −$510M (15 Oct) |
What management said, and what happened
FMC’s market has been hard: generics after the Rynaxypyr patent expiry, weak grower margins and low insect pressure. Debt reduction is the promise most on track.
| Topic | What management said | What happened | Outcome |
|---|---|---|---|
| The 2026 low point | Feb: A Q1 margin of about 7%, unique to Q1, then recovery Apr: The first half will be the earnings trough Jul: All the reasons in the world to believe 2026 is the trough | Q3 adjusted EBITDA now guided at −$565M to −$510M (15 October). | Missed |
| Full-year EBITDA | Feb: $670M to $730M Apr: Guidance ranges unchanged | Cut to $620M to $680M in July. | Missed |
| Covenants | Feb: A good plan to manage within the existing covenants (6.0x through 2026) Jul: Comfortably in compliance | Test suspended for Q2 and Q3 in April; in October FMC said it will seek further covenant modifications over the next year. | Changed |
| The channel | Feb: Distributors reluctant to fully stock Rynaxypyr Jul: Distributors shifting orders from Q3 to Q4 | High-priced FMC stock held by distributors, a move away from the US high-rebate model, and $625M to $675M of actions. FMC said the issue had been addressed “incrementally over several quarters”. | Reversed |
| Debt reduction | Feb: Over $1B of debt paydown in 2026 from asset sales and licensing | About $1B of deals announced (India, Corteva, Newark, Tessenderlo); most still to close at June 30. | Kept |
| Commitment | What they said | Result |
|---|---|---|
| Q3 revenue | $840M to $900M | Missed: now $65M to $125M (15 Oct) |
| Q3 adjusted EBITDA | $120M to $140M | Missed: now −$565M to −$510M (15 Oct) |
| Q4 | A return to year-over-year growth; revenue $1.06B to $1.20B | Awaiting |
| Full-year free cash flow | $75M to $225M | Awaiting |
| Year-end net debt | About $2.6B, roughly 4x EBITDA | Awaiting |
| Covenants | Comfortably in compliance; total leverage tested again in Q4 at 6.75x | Awaiting |
| Inventory | Very significant progress on the inventory situation this year | Awaiting |
| 2026 as the trough | All the reasons in the world to believe 2026 is the trough | Awaiting |
8 questions, checked against the call
Raised by the 10-Q. To be tested again at Q3 results on 29 October.
Investor relations: Curt Brooks, Director of Investor Relations · curt.brooks@fmc.com
What this does and does not show
A possible material non-cash impairment in Q3
Not flagged in the Q2 read. Goodwill was written off in full in Q4 2025 ($1,356.2M), so any new charge falls on the $2.31B of other intangibles or on other long-lived assets. No cash effect, but it reduces equity, which stood at $1.66B at June 30.
Not discussed on a call; disclosed in the 15 October update.
What would resolve this: Q3 results quantify the charge.
Nothing here shows misstatement or a covenant breach.
The rebate accrual is FMC’s own estimate of what it owes customers, and rebates build every first half; the question is how much of the year depended on concessions still to come. The covenant was amended with lender support, and more than $1.56B of the revolver was available at June 30.
- Concessions booked against the existing accrual
- Q4 covenant test met without another amendment
- Channel stock cleared by year-end
- Full-year free cash flow guidance held
- Charges beyond the $625M to $675M already set out
- Another covenant amendment or waiver
- Q4 guidance cut
- The dividend kept while cash guidance falls
Evidence & Outcomes Ledger
A chronological record separating original evidence, historical analysis and subsequent developments.
Q2 2026 10-Q filed
FMC published its quarterly financial statements. The earnings release and call were also part of the original research evidence.
View SEC filing ↗Original forensic report shared
Research covering customer rebates of $632.4M, leverage covenant considerations and the $200M Corteva prepayment was shared externally before the October disclosure. The original dated report should be retained as the immutable evidence of what was known at this stage.
Subsequent FMC disclosure
FMC disclosed $625M–$675M of commercial actions, including distributor pricing changes and a move away from its US high-rebate model. It also discussed potential further covenant modifications and impairment risk.
Read subsequent disclosure ↗Current assessment updated
Rebates: Confirmed as a relevant channel-pricing concern. Covenants: Escalated. Corteva prepayment: Open. Potential impairment: Newly identified after the September analysis, not an original finding.
The later commercial-actions amount is not the same accounting measure as the original rebate accrual. Status changes reflect later evidence, not a claim that the exact October outcome was predicted.
Every figure ties back to the filing
| Form 10-Q, Q2 2026 | Open ↗ |
| Form 10-K, FY 2025 | Open ↗ |
| Q2 2026 earnings release | Open ↗ |
| Update to Q3 expectations, 15 October 2026 | Open ↗ |
| Earnings call transcripts, Q4 2025 to Q2 2026 | Third-party transcripts |
Helmledgers reads the full filing, including the notes, and ties every figure to the statement or note it comes from. Findings are ranked by how far the filing departs from the company’s own narrative and how easily they are missed in standard coverage. Earnings calls are read against the filing to record what management answered, sidestepped or left out. This is an accounting read of public SEC filings. It is not an audit opinion and not investment advice.
- Severity
- High: material effect on cash, debt or reported results. Medium: worth tracking, smaller or less certain effect.
- On the call
- Direct answer, Partly answered (topic addressed, figure missing), Sidestepped (raised but not answered) or Not asked.
- Since the read
- Confirmed by a later disclosure, Escalated (grown since), Open (untested) or Missed (not flagged by the read).
- Said versus done
- Kept, Slipped (late), Changed (plan or terms changed), Missed or Reversed.
- Markers
- Measurable checks set before results, each with what would widen or close the gap. Scored after the next results.
- Closes if
- The evidence that would resolve a finding.
Positions: Helmledgers holds no position in FMC. This analysis is an accounting read of public SEC filings and does not constitute investment advice.
This is an accounting read of public SEC filings. It is not an audit opinion and not investment advice.